First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trialLin Shen, Lin Xie, Wenxiang Dai et al.|Nature Medicine|2025Cited by 89